Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines

  • Arcturus Therapeutics Holdings Inc ARCT announced a strategic collaboration with CSL Seqirus, a unit of CSL Limited CSLLY
  • Under the terms of the agreement, Arcturus will provide CSL Seqirus with a license to their self-amplifying mRNA technology to support the research, development, manufacture, and commercialization of vaccines for SARS-CoV-2 (COVID-19), influenza, pandemic-preparedness, as well as three other globally prevalent respiratory infectious diseases.
  • The collaboration combines CSL Seqirus' established global vaccine commercial and manufacturing infrastructure with Arcturus' manufacturing expertise and STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies.
  • Related Content: Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants
  • CSL Seqirus will lead the development and commercialization of vaccines under the collaboration. 
  • Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and over $3 billion in commercial milestones. 
  • In addition, Arcturus is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to double-digit royalties for vaccines against flu, pandemic preparedness, and three other respiratory pathogens.
  • Price Action: ARCT shares are up 31.84% at $24.10 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccinepremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!